Fig. 3: circKIF4A facilitates glioma growth and temozolomide resistance in vivo.
From: CircKIF4A promotes glioma growth and temozolomide resistance by accelerating glycolysis
A Subcutaneous tumorigenesis assays were conducted on nude mice. Overexpression of circKIF4A increased the growth rate and tumor volume. Inhibition of circKIF4A reduced the growth rate and the volume of tumors established by SHG-44 glioma cells. B Temozolomide resistance of glioma was evaluated after overexpression and knockdown of circKIF4A in vivo. C An orthotopic glioma model was established via intracranial injection of OE-NC or OE-circKIF4A group SHG-44 tumor cells. D An orthotopic glioma model was established via intracranial injection of sh-NC or sh-circKIF4A group A172 tumor cells. E The overall survival of mice evaluated by Kaplan–Meier survival analysis was decreased after upregulation of circKIF4A in orthotopic glioma models (OE-circKIF4A group). F The overall survival of mice evaluated by Kaplan–Meier survival analysis was prolonged after downregulation of circKIF4A in orthotopic glioma models (sh-circKIF4A group). G Representative images of Ki-67 (marker of proliferation) immunohistochemical staining in xenograft sections. **p < 0.01. The experiment was repeated three times independently.
